Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Perpetua Medical AB's Debt-to-EBITDA or its related term are showing as below:
PPTMF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.27 Med: -0.08 Max: 0.05
Current: 0.05
During the past 12 years, the highest Debt-to-EBITDA Ratio of Perpetua Medical AB was 0.05. The lowest was -0.27. And the median was -0.08.
PPTMF's Debt-to-EBITDA is ranked better than 95.31% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs PPTMF: 0.05
Perpetua Medical AB (OTCPK:PPTMF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Perpetua Medical AB Debt-to-EBITDA Related Terms
Perpetua Medical AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Perpetua Medical AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Perpetua Medical AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perpetua Medical AB Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Perpetua Medical AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Perpetua Medical AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Perpetua Medical AB (PPTMF) has a Debt-to-EBITDA of -0.03 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Perpetua Medical AB. According to the industry distribution chart, Perpetua Medical AB ranks #22 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 4.7%.
Is Perpetua Medical AB's Debt-to-EBITDA too high?
Perpetua Medical AB's current Debt-to-EBITDA is -0.03. Based on the distribution chart, Perpetua Medical AB ranks #22 out of 469 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Perpetua Medical AB has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Perpetua Medical AB's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Perpetua Medical AB ranks #22 out of 469 companies for Debt-to-EBITDA. This places Perpetua Medical AB in the top 5% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Perpetua Medical AB. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perpetua Medical AB's current Debt-to-EBITDA is -0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perpetua Medical AB stock overvalued right now?
Perpetua Medical AB (PPTMF) has a current Debt-to-EBITDA of -0.03. The stock's GF Value™ is $1.22, compared to a current price of $1.08 — trading 11.6% below its estimated fair value. The current Debt-to-EBITDA is -0.03. Perpetua Medical AB's overall GF Score™ is 57/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Perpetua Medical AB (PPTMF), the current Debt-to-EBITDA is -0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perpetua Medical AB (PPTMF) Overvalued in 2026?
Based on GuruFocus' analysis, Perpetua Medical AB stock appears to be undervalued.
The current stock price of $1.08 is trading 11.6% below its estimated GF Value™ of $1.22.
Key valuation signals for PPTMF:
Debt-to-EBITDA: -0.03
GF Value™: $1.22 vs. price of $1.08 (11.6% below fair value)
No single metric tells the full story. See the PPTMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perpetua Medical AB is engaged in healthcare sector. The company develops systems and solutions that plan to optimize and ensure correct and effective treatment with injectable drugs. Its products include WasteLog and Pharmacolog Dashboard.
57GF Score
Get the complete analysis for PPTMF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PPTMF has been successfully added to your 
